Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  
Facebook    Twitter     Linkedin     RSS     Google+    BLOG    You Tube
 

Journal of Antivirals & Antiretrovirals


Open Access
 
 
 
ISSN: 1948-5964
 
 
 
HOME » ANTIVIRALS-ANTIRETROVIRALS
French Language  |  English
 
 
 
 
 
 
SCImago Journal & Country Rank
 

About the Journal

Welcome Message
Welcome to the Journal of Antivirals and Antiretrovirals (JAA): An open-access, multidisciplinary journal for the discovery and development of antiviral drugs.

I welcome you to a truly interdisciplinary journal which attracts the interest of scientists from various fields such as systems biology, chemistry, virology, and the clinical sciences.
 
Impact Factor: 3.25*
Index Copernicus Value: 4.86
H-Factor: 2

The Journal of Antivirals & Antiretrovirals (JAA) paves the way to discovery and development of antiviral drugs, compounds, and clinical methods to prevent viral infections. Importantly, JAA provides the opportunity to inform researchers, clinicians, and others working in the field of antiviral drugs and therapies. JAA is an internationally recognized journal for scientists involved in basic, applied, and clinical aspects of antiviral and antiretroviral research. It is known that many viruses emerge and re-emerge threatening both animal and human populations. Zoonotic viruses can cause extensive morbidity and mortality; however, preventive vaccines that provide protection are available for only a limited number of viruses.
flyer image

ISSN: 1948-5964
NLM ID: 101526954
 
The primary current therapeutic approach against viral diseases is to target viral components that are essential for replication. There are a number of disadvantages targeting viral components including the limited number of druggable viral targets because viruses have a small genome, as well as the rapid development of drug resistance. New drug therapies combine antivirals to increase efficacy and to avoid the development of drug resistant strains. These strategies are effective for viruses such as HIV, but clearly there is a need to expand our drug arsenal to address the wide diversity of viruses. This pathway relies on alternative strategies for drug discovery, such as examining the virus-host interface.
 
High-throughput RNA interference (RNAi) technology is a platform-enabling technology that allows for rapid searching and validation of biologically relevant target genes in the host. RNAi can be used to silence each and every gene in a host to ask what genes are needed for virus replication. Perhaps the greatest challenge is identify and validate the host genes and pathways they intersect among all the interactions relevant to virus replication. Here, antiviral drugs targeting host genes/factors can be discovered that markedly expand the number of druggable targets that can be temporarily silenced to prevent virus replication. This genome-wide exploration of virus-host interactions allows for a paradigm change in drug discovery because it provides critical host gene/pathway information allowing for drug rescue and repurposing. This systems-based approach to antiviral drug discovery integrates multiple ‘-omics’ approaches because much is learned about host genes co-opted by the virus for metabolomics, and proteins usurped for viral protein trafficking and viral packaging (proteomics), and the like. This information helps to find drugs lacking undesired side effects, and uses a rational approach in drug screening.
 
As the Editor-in-Chief of Journal of Antivirals & Antiretrovirals, I believe the strength of this open access journal is determined by the quality of manuscripts that it receives, and by the assembly of its editorial board that must encourage contributions from leading investigators. As JAA is an open-access, multidisciplinary journal for the discovery and development of antiviral drugs, it allows for rigorous review and rapid publication without unnecessary delay or expense. I expect JAA to become a venue for top-quality manuscripts and look forward to reading your contributions. Best.
 

Editor-in-Chief
Bindong Liu
Center for AIDS Health Disparities Research School of Medicine
Meharry Medical College
USA

 

 

 

Recently published articles

Host Cell Redox-Regulated Pathways as Targets for Novel Anti-influenza Strategy

Rossella Sgarbanti1, Donatella Amatore2,3 and Lucia Nencioni3

 
Is Interferon-Free Treatment for HCV Possible?

Shan Chen1, Shilin Li1, Bing Liu1, Li Ma1, and Limin Chen1,2

 
Countermeasures to Address the Ebloa Virus (EBOV) Threat

Ralph A Tripp

 
HLA-G and Virus Infection

Wei-Hua Yan

 
Preclinical and Clinical Profile of HIV-1 Integrase Strand-transfer Inhibitor GS-9224 Compared to its Parent Compound GS-9160

Gregg S Jones, Rebecca Hluhanich, Lani M Wieman, Jim Zheng, Wayne Huang, April Kinkade, Eugene J Eisenberg, Chris Yang, Damian
McColl, Anita Mathias, Haolun Jin, Tomas Cihlar, Matthew Wright, Romas Geleziunas and Manuel Tsiang

 
Blue Eye Disease in Dog with Hyperthermia at Pindi Bhattian District Hafizabad, Pakistan

Sohail Manzoor1, Zahid Hussain2 and Muhammad Mukhtar3

 
New Antiretroviral Therapies and Potential Drug Interactions in HIVInfected Drug Abusers

PSS Rao1, TJ Cory2 and S Kumar1

 
Reactivation of Hepatitis B Virus Infection Associated with Anti-Tumor Necrosis Factor-α Therapy

Lorenzo Nobili†, Lisa Albani†, Armando Gabrielli and Gianluca Moroncini

 
Metformin and Resveratrol Induce Beneficial Metabolic Adaptations in L6 Muscle Cells Treated with HIV Protease Inhibitors: Evidence for Inhibition of JNK1/2 Signaling

Lindsey D Bogachus and Lorraine P Turcotte

 
Antiviral Activity of Sirna UL42 against Herpes Simplex Virus Type 1 in HeLa Cell Culture

Hamid Reza Mollaei1, Seyed Hamidreza Monavari2, Seyedalimohammad Arabzadeh3, Mahmood Shams Shahrabadi2 and Mehdi
Fazlalipour1

 
Level of ART Adherence and Associated Factors among HIV Sero- Positive Adult on Highly Active Antiretroviral Therapy in Debre Markos Referral Hospital, Northwest Ethiopia

Mulugeta Asmare1, Mekonnen Aychiluhem2, Mulatu Ayana1 and Dube Jara1

 
The Prediction of Integrase Inhibitors Efficacy in Third Line Regimen after First and Second Line Antiretroviral Therapy Failure in Senegal

Edmond Tchiakpe1, Abou Abdallah Malick Diouara1, Moussa Thiam1, Halimatou Diop Ndiaye1, Ndeye Fatou Ngom-Gueye2, Nafissatou
Leye1, Makhtar Ndiaga-Diop2, Yao Mawulikplimi Adzavon1, Khady Kébé Fall1, Amina Sow Sall1, Aïssatou Gaye Diallo1, Souleymane Mboup1
and Coumba Toure-Kane1

 
Birth Outcomes in HIV-1-Infected Women Receiving Highly Active Antiretroviral Therapy (HAART) Prior to Conception versus During Pregnancy in Yaoundé, Cameroon

Anne Esther Njom Nlend1,2, Cecile Zeudja1,2, Suzie Moyo1, Annie Nga Motaze1 and The Therapeutic Committee of Centre Hospitalier
d’ESSOS Djoungolo

 
Recombinant Coree1e2 Protein Expressed in Pichia pastoris Yeast a Candidate Vaccine for Hepatitis C Virus

Mehdi Fazlalipour, Hossein Keyvani, Seyed Hamid Reza Monavari and Hamid Reza Mollaie

 
Antiretroviral Toxicity Leading to a Medication Change in Multiple HIV Clinics in Resource Limited Settings

Thomas Macharia, Anthony Amoroso, Martine Etienne-Mesubi and Anthony Edozien

 
 
 
 
 
Meet us at our 300+ Global Events in Pharma, Medicine, Science and Technology

Our 2015 Major destinations:
Conferences By Country USA
USA  USA Spain  Spain
Australia  Australia Canada Canada
UAE  UAE China China
Italy  Italy France France
Germany  Germany India India
UK  UK Malaysia Malaysia
Japan  Japan singapore Singapore
France  Brazil South Africa South Africa
South Korea South Korea
 
Conferences By City USA
Chicago Valencia Beijing
Florida Alicante Houston
Philadelphia Rome San Antonio
Baltimore Birmingham Abu Dhabi
Boston Lexington Las Vegas
Seattle Atlanta Barcelona
New Orleans Brisbane San Francisco
Bengaluru New Delhi Toronto
Dubai London Hyderabad
 
Conferences By Subject USA
Medical Pharma Veterinary
Agri, Food & Aqua Genetics Molecular Biology
Physics Health care Neuroscience
Chemistry Immunology Nursing
Clinical Massmedia Physics
Environmental Materials Science Microbiology
EEE Environmental  
Chemical Engineering Business & Management
 
 
© 2008–2014 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version